| Sep 10 |
BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)
|
| Sep 10 |
BridgeBio Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program
|
| Sep 4 |
BridgeBio draws bullish view at Piper on potential acoramidis nod
|
| Aug 31 |
BridgeBio: With HELIOS-B Overhang Removed, Focus To Turn To Approval And Launch Of Acoramidis
|
| Aug 30 |
Alnylam Stock Falls on Positive but Disappointing Study Results for Heart Drug
|
| Aug 30 |
Alnylam tumbles, BridgeBio gains after heart drug data
|
| Aug 30 |
Why Is BridgeBio Pharma Stock Trading Higher On Friday?
|
| Aug 30 |
BridgeBio Pharma Reports Positive Additional Data From Phase 3 Study of Acoramidis; Shares Rise
|
| Aug 30 |
BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension
|
| Aug 29 |
BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024
|
